Calliditas Therapeutics AB banner

Calliditas Therapeutics AB
NASDAQ:CALT

Watchlist Manager
Calliditas Therapeutics AB Logo
Calliditas Therapeutics AB
NASDAQ:CALT
Watchlist
Price: 40.0001 USD Market Closed
Market Cap: $1.1B

Wall St Price Targets

CALT Price Forecast
No price targets yet

We don't have analyst price targets for CALT yet.

CALT Analyst Rating
No ratings yet

No rating

We don't have analyst ratings for CALT yet.

Calliditas Therapeutics AB Competitors:
Price Targets

Revenue
Forecast

N/A
Past Growth
57% / Year
Estimated Growth
Estimates Accuracy
4%
Average Beat
N/A
Past Growth
57% / Year
Estimated Growth
Estimates Accuracy
4%
Average Beat

The compound annual growth rate for Revenue over the next 3 years is 57%.

Gross Profit
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Gross Profit Forecast
is not available for Calliditas Therapeutics AB

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-17%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-17%
Average Miss

Pre-Tax Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Pre-Tax Income Forecast
is not available for Calliditas Therapeutics AB

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Net Income Forecast
is not available for Calliditas Therapeutics AB
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is CALT's stock price target?
Not Available

CALT does not have any price targets made by Wall Street professionals.

What is the Revenue forecast for Calliditas Therapeutics AB?
Projected CAGR
57%

The compound annual growth rate for Revenue over the next 3 years is 57%.

Back to Top